Journal Information
Vol. 99. Issue 1.
Pages 34-43 (January - February 2008)
Share
Share
Download PDF
More article options
Vol. 99. Issue 1.
Pages 34-43 (January - February 2008)
Practical dermatology
Full text access
Diagnosis and Management of Nail Psoriasis
Aspectos Diagnósticos y Terapéuticos de la Psoriasis Ungueal
Visits
9811
M Sánchez-Regaña
Corresponding author
ez.reg@terra.es

Correspondence: Unidad de Psoriasis y Fototerapia, Servicio de Dermatología, Hospital Universitario Sagrado Corazón, París, 83-87 5.ª planta, 08029 Barcelona, Spain.
, P Umbert
Unidad de Psoriasis y Fototerapia, Servicio de Dermatología, Hospital Universitario Sagrado Corazón, Barcelona, and Unidad Docente de la Universidad de Barcelona, Barcelona, Spain
This item has received
Article information
Abstract

Nail psoriasis has traditionally been considered as one of the most difficult forms of psoriasis to treat. The most recent studies have found a higher prevalence of fungal infections in psoriatic nails and therefore cultures before and during treatment are necessary. Over the last few years, novel psoriatic therapies have been developed, some of which are effective for both skin and nail lesions (cyclosporine and biologic agents). Of the topical agents, vitamin D and A derivatives as well as nail lacquer containing 8% clobetasol propionate can help improve lesions of both the nail bed and matrix.

Key words:
psoriasis
nails
diagnosis
management
Resumen

La psoriasis ungueal ha sido considerada clásicamente una de las manifestaciones más difíciles de tratar de la enfermedad. Los últimos estudios han evidenciado una mayor prevalencia de infecciones fúngicas en las uñas psoriásicas, por lo que debemos practicar cultivos al inicio y durante el tratamiento. En los últimos años han aparecido numerosas novedades terapéuticas en la psoriasis; algunas son eficaces tanto para las lesiones cutáneas como para las ungueales (ciclosporina y biológicos). A nivel tópico, los derivados de la vitamina D y A, así como la laca de clobetasol propionato al 8% pueden conseguir mejorar tanto las lesiones del lecho como las de la matriz ungueal.

Palabras clave:
psoriasis
uñas
diagnóstico
tratamiento
Full text is only aviable in PDF
References
[1.]
E.M.G.J. De Jong, B.A. Seegers, M.K. Gulinck, J.B. Boezeman, P.C. van de Kekhof.
Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients.
Dermatology, 193 (1996), pp. 300-303
[2.]
M. Sánchez Regaña, M. Iglesias, L. Creus, P. Umbert.
Prevalencia de enfermedades hepáticas crónicas en pacientes con psoriasis.
Actas Dermosifiliogr, 91 (2000), pp. 498-510
[3.]
A. Tosti, R. Morelli, Bardazzi, B.M. Piraccini.
Psoriasis of the nails.
Psoriasis, pp. 201-207
[4.]
M. Lawry.
Biological therapy and nail psoriasis.
Dermatologic Therapy, 20 (2007), pp. 60-67
[5.]
M. Sánchez Regaña, R. Ojeda, I. Umbert, P. Umbert, W. Lupo, J. Solé.
El impacto psicosocial de la psoriasis.
Actas Dermosifiliogr, 94 (2003), pp. 11-16
[6.]
E. Duhard-Brohan.
Psoriasis unguéal.
Ann Dermatol Venereol, 126 (1999), pp. 445-449
[7.]
R.L. Rudolph.
Lithium-induced psoriasis of the fingernails.
J Am Acad Dermatol, 26 (1992), pp. 135-136
[8.]
E. Szepes.
Mycotic nail fold infections of psoriatic nails.
Mykosen, 29 (1986), pp. 82-84
[9.]
A.K. Gupta, C.W. Lynde, H.C. Jain, R.G. Sibbald, B.E. Elewski, C.R. Daniel, et al.
A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study.
Br J Dermatol, 136 (1997), pp. 786-789
[10.]
Sánchez Regaña M, Videla S, Villoria J, Domingo E, Macaya A, Ortiz E, et al. Report on the prevalence of fangal involvement in a series of patients with nail psoriasis. Clin Exp Dermatol. En prensa 2007.
[11.]
P.H. Rich, R.K. Scher.
Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis.
J Am Acad Dermatol, 49 (2003), pp. 206-212
[12.]
C.A. Parrish, J.O. Sobera, B.E. Elewski.
Modification of the nail psoriasis severity index.
J Am Acad Dermatol, 53 (2005), pp. 745-747
[13.]
D. De Berker.
Management of nail psoriasis.
Clin Exp Dermatol, 25 (2000), pp. 357-362
[14.]
R. Baran, A. Tosti.
Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation.
J Dermatol Treat, 10 (1999), pp. 201-204
[15.]
M. Sánchez Regaña, G. Martín, P. Umbert, F. Llambí.
Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients.
[16.]
X. García-Navarro, E. Serra-Baldrich, E. Roé, F. Corella, J. Dalmau, D. Barco, et al.
Acute onset of “green nails” after treatment with 8% clobetasol nail lacquer.
Proceedings of the 16th European Academy of Dermatology and Venereology, pp. 16-20
[17.]
M. Sánchez Regaña, R. Ojeda, P. Umbert.
Empleo de calcipotriol tópico en la psoriasis ungueal.
Piel, 17 (2002), pp. 104-108
[18.]
D. Rigopoulos, D. Loannides, N. Prastitis, A. Katsambas.
Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream.
Acta Derm Venereol, 82 (2002), pp. 140
[19.]
G. Márquez, M. Sánchez Regaña, E. Herrera, I. Vidal, L. Galvany, P. Umbert.
Tratamiento de la psoriasis ungueal con laca de clobetasol 8% y ungüento de tacalcitol.
Proceedings of the XXXV Congreso Nacional de la Academia Española de Dermatología y Venereología, pp. 13-16
[20.]
L. Bianchi, R. Soda, L. Diluvio, S. Chimenti.
Tazarotene 0,1% gel for psoriasis of the fingernails and toenails: an open prospective study.
Br J Dermatol, 149 (2003), pp. 207-209
[21.]
R.K. Scher, M. Stiller, Y.I. Zhu.
Tazarotene 0,1% gel in the treatment of fingernails psoriasis: a double-blind, randomized, vehicle-controlled study.
Cutis, 68 (2001), pp. 355-358
[22.]
D. Rigopoulos, S. Gregoriou, A. Katsambas.
Treatment of psoriatic nails with taza rotene cream 0,1% vs. clobetasol propionate 0,05% cream: a double-blind study.
Acta Derm Venereol, 87 (2007), pp. 167-168
[23.]
T. Frederiksson.
Topically applied fluorouracil in the treatment of psoriatic nails.
Arch Dermatol, 110 (1974), pp. 735
[24.]
K. Fritz.
Psoriasis of the nails. Successful topical treatment with 5-fluorouracil.
Z Hautkr, 64 (1988), pp. 1083-1088
[25.]
T. Yamamoto, I. Katayama, K. Nishioka.
Topical anthralin therapy for refractory nail psoriasis.
J Dermatol, 25 (1988), pp. 231-233
[26.]
A. Tosti, L. Guerra, F. Bardazzi, M. Lanzarini.
Topical ciclosporin in nail psoriasis.
Dermatológica, 180 (1990), pp. 110
[27.]
R. Ojeda, M. Sánchez Regaña, J. Massana, R. Oliete, P. Umbert.
Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
J Dermatol Treat, 16 (2005), pp. 338-341
[28.]
G. Mahrle, H.J. Schulze, L. Faerber, G. Weidinger, G.K. Steigleder.
Low–dose short-term ciclosporin versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
J Am Acad Dermatol, 32 (1995), pp. 78-88
[29.]
E. Herrera, M. Sánchez Regaña, I. Vidal, L. Galvany, G. Márquez, J. Molinero, et al.
Efalizumab: experiencia en la psoriasis.
Proceedings of the XXXV Congreso Nacional de la Academia Española de Dermatología y Venereología, pp. 13-16
[30.]
I. Vidal, M. Sánchez Regaña, E. Herrera, L. Galvany, G. Márquez, P. Umbert.
Etanercept: seguimiento durante 2 años en pacientes con psoriasis.
Proceedings of the XXXV Congreso Nacional de la Academia Española de Dermatología y Venereología, pp. 13-16
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?